In association with

getting

personal

Precision medicine is poised to revolutionise pharma, but what does that mean for manufacturing?

SPECIAL ISSUE I OCTOBER 2018

The economics of CAR-T therapy

Identifying new drug combinations using AI 

Microbiome vs genome

02/24/2024 08:51:30
  • Home | Getting Personal
  • Scandinavian Health Ltd. Company Insight
  • Scandinavian Health Ltd.
  • In this issue
  • International Cannabis and Cannabinoid Institute (ICCI) Company Insight
  • International Cannabis and Cannabinoid Institute (ICCI)
  • Contents
  • Novo Nordisk
  • News
  • Phoenix
  • The Pharma Industry Briefing
  • Nelson Lab Company Insight
  • Nelson Labs
  • Manufacturing personalised meds: what needs to change?
  • Molnar Company Insight
  • Molnar
  • Selling cells: the economics of CAR-T therapy
  • Wilhelm Haselmeier GmbH & Co KG Company Insight
  • Wilhelm Haselmeier GmbH & Co. KG
  • Using AI to personalise drug combination therapy
  • NSF
  • Is the microbiome as important for precision medicine as genetics?
  • Nipro PharmaPackaging
  • A summer of manufacturing disasters for Chinese pharma
  • Capsugel
  • Endoca
  • ContraFect’s Staph infection drug may succeed in trial but caveats remain
  • Dow Europe GmbH Company Insight
  • Dow Europe GmbH
  • Why are novel therapies for glioblastoma patients not gaining approvals?
  • Lubrizol Life Sciences
  • QualiMetriX
  • CAR-T approved in Europe but NICE verdict is divided: what happens next?
  • Palleos healthcare GmbH
  • Daiichi Jitsugyo
  • Events
  • Nemera Company Insight
  • Erdmann Design Switzerland
  • Next issue
  • Nemera
  • Plastiape
  • General Electric Healthcare
09/28/2018 00:00:00